^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Gastroesophageal Junction Adenocarcinoma |
| Drug: | capecitabine (Thymidylate synthase inhibitor) + oxaliplatin (DNA synthesis inhibitor, DNA cross linking agent) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
…the panel recommends capecitabine and oxaliplatin as an option for postoperative chemotherapy in patients with resectable esophageal or EGJ cancers who had not received preoperative therapy.
